Background: Pulmonary sarcomatoid carcinoma (PSC) is a recognized category of highly aggressive and poorly differentiated non-small-cell lung carcinoma (NSCLC), with five different subtypes: pleomorphic, spindle, giant cell, carcinosarcoma, and pulmonary blastoma. Although uncommon (0.1% to 0.4% of all pulmonary malignancies), their clinical importance is underscored by poorer prognosis and higher rate of resistance to conventional chemotherapy than other NSCLCs. And the incidence of MET 14 skipping in PSC is controversial. The aim of this study was to reveal the reliable frequency and the clinical-pathologic characteristics of PSC with MET 14 skipping in Chinese population. Method: A total of 35 patients with PSC were recruited between September 2007 and December 2017. The status of MET 14 skipping was detected by reverse transcription polymerase chain reaction (RT-PCR). Results: Of this study, three patients were identified with MET 14 skipping in Chinese PSC population (2.86%, 1/35). The patient was a pulmonary pleomorphic carcinoma (PPC). Background: Recombinant human endostatin was an inhibitor of tumor angiogenesis that transiently normalizes the tumor vasculature. Our previous study showed that continuous intravenous pumping of Endostar with concurrent radiochemotherapy promised short-term tumor control outcome in patients with NSCLC patients. Our study is to evaluate efficacy of continuous intravenous pumping of Endostar combined with SBRT for elderly patients with early stage non-small cell lung cancer. Method: This retrospective study was approved by our institutional IRB. Between Nov. 2016 and Oct. 2017, 40 patients were enrolled in the study, including 16 (40%) patients were diagnosed with squamous cell carcinoma, 20 (50%) with adenocarcinoma; 15 (37.5%) with stage I disease and 25 (62.5%) with IIa (T2bN0M0) disease, respectively. The average age was 71 (63-84) years. CT or PET-CT were obtained to exclude mediastinal or supraclavicular lymph nodes metastasis. For all patients, the total dose of SBRT was 50Gy in 5 fractions. Some patients received continuous intravenous pumping of Endostar (15mg/ m2/d) delivered over 7 days with concurrent SBRT, followed by 2 more courses of Endostar at one and three months after SBRT. The side effect and short-term tumor control were assessed at one month, three months and six months after the end of SBRT. Results: group A included 18 patients with stage I or IIa NSCLC who received SBRT and continuous pumping of Endostar. Group B included 22 patients who received SBRT alone. The median follow-up was 10 months. At the first month, 3 patients (16.7%) in group A and 7 patients (31.8%) in group B developed grade 2 pneumonitis, (P¼0.008). At 3 and 6 months, pneumonitis resolved in 1 patient, but another patient was diagnosed with grade 2 pneumonitis/fibrosis in group A, while in group B, one pneumonitis resolved and another three patients were diagnosed grade 2 and 3 pneumonitis or fibrosis (22.2% vs 40.9%, P¼0.038). At the last followup, 7 patients (38.9%) were CR or PR, 5 patients (27.8%) were SD in group A, and 8 patients (36.4%) were CR or PR, 5 patients (22.7%) were SD in group B (P¼0.419). Conclusion: There is a significant difference in radiation pneumonitis risk between patients treated with SBRT with and without Endostar. Recombinant human endostatin combined with SBRT could reduce the rate of pneumonitis and fibrosis compared with SBRT alone. Endostar does not increase other side effects or affect short term tumor control. Further prospective randomized control studies are needed to evaluate the clinical efficacy of this combined treatment modality. Keywords: SBRT, NSCLC, early stage, old patient . Propensity score match analysis is utilized to balance the baseline characteristics. Results: A total of 686 SCLC with IA stage were included; 337 patients received surgery and 349 patients were treated by CRT alone. Patients received surgery presented better outcome than CRT alone, with the 5-year estimated overall survival (OS) of 50.0% and 24.7%, respectively (adjusted HR¼0.495, 95%CI, 0.401-0.611). The median survival duration is longer in patients who received lobectomy or extended lymphadenectomy (lobectomy vs. sublobectomy, 67 months vs. 38 months in matched cohort, p¼0.223; ELN>7 vs. ELN7, 91 months vs. 54 months, p¼0.105). Additional chemo/radiotherapy is associated with longer survival in patients who received lobectomy. For SCLC patients with IA stage, the best prognosis is observed in patients who received lobectomy plus chemotherapy and radiotherapy and the 5-year survival rate is 73.5% (Figure 1) . Conclusion: Lobectomy plus CRT as a component of treatment is associated with significantly longer survival than other treatment modality and should be considered in the management of SCLC with IA stage. Keywords: surgery, chemothreapy, radiotherapy, small cell lung cancer
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